<br>        Inclusion Criteria:<br><br>          -  Subjects aged 18 years or older, at the time of signing the informed consent.<br><br>          -  Subjects with documented physician diagnosis of asthma as their primary respiratory<br>             disease.<br><br>          -  ACT score <20 at screening visit.<br><br>          -  Non-smokers (never smoked or not smoking for >6 months with <10 pack years history<br>             (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked).<br><br>          -  Male or female subjects will be included. A female subject is eligible to participate<br>             if she is not pregnant, not breastfeeding, and at least one of the following<br>             conditions applies: (i) Not a woman of childbearing potential (WOCBP). (ii) A WOCBP<br>             who agrees to follow the contraceptive guidance during the treatment period and for at<br>             least 5 days] after the last dose of study treatment.<br><br>          -  Capable of giving signed informed consent which includes compliance with the<br>             requirements and restrictions listed in the consent form and protocol.<br><br>          -  Subject understands and is willing, able, and likely to comply with study procedures<br>             and restrictions.<br><br>          -  Subject must be able to read in a language supported by the smart phone app in their<br>             region.<br><br>          -  Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3<br>             months, cannot have changed dose in the month prior to screening and be able to change<br>             to an equivalent dose of RELVAR/BREO for the duration of the study. Other background<br>             asthma medication such as anti-leukotrienes and oral corticosteroids are permitted<br>             provided the dose has been stable for 1 month prior to screening.<br><br>          -  Subject must be able to change to Salbutamol/Albuterol MDI rescue for the duration of<br>             the study and judged capable of withholding albuterol/salbutamol for at least 6 hours<br>             prior to study visits.<br><br>          -  Subject must have their own Android or iPhone operating system (IOS) smart phone and a<br>             data package suitable for the installation and running of the app and sending and<br>             receiving data. Data used by the CIS is approximately 1 megabyte (MB) per month as a<br>             maximum; this is less data than a 1 minute video streamed from YouTube (2MB).<br><br>          -  Subjects must be willing and able to download the app on their personal smart phone<br>             and keep it turned on for the duration of the study. This will also require Bluetooth<br>             to be turned on for duration of the study. Subjects will also have to turn on mobile<br>             data for the app for the duration of study; unless travelling and when extra data<br>             roaming costs could be incurred.<br><br>        Inclusion criteria for randomization:<br><br>          -  ACT score <20 at randomization visit (visit 2).<br><br>        Exclusion Criteria:<br><br>          -  Subjects with a known or suspected alcohol or drug abuse which in the opinion of the<br>             investigator could interfere with the subject's proper completion of the protocol<br>             requirement.<br><br>          -  History of life threatening asthma: Defined as an asthma episode that required<br>             intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic<br>             seizures within the last 6 months.<br><br>          -  A lower respiratory tract infection within 7 days of the screening visit.<br><br>          -  Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other<br>             respiratory disorders including active tuberculosis, lung cancer, bronchiectasis,<br>             sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or<br>             other active pulmonary diseases.<br><br>          -  History of hypersensitivity/intolerance to any components of the study inhalers<br>             (example, lactose, magnesium stearate). In addition, subjects with a history of severe<br>             milk protein allergy that, in the opinion of the study physician, contraindicates<br>             participation will also be excluded.<br><br>          -  Historical or current evidence of clinically significant or rapidly progressing or<br>             unstable cardiovascular, neurological, cardiovascular, neurological, renal, hepatic,<br>             immunological, endocrine (including uncontrolled diabetes or thyroid disease) or<br>             hematological abnormalities that are uncontrolled. Significant is defined as any<br>             disease that, in the opinion of the investigator, would put the safety of the subject<br>             at risk through participation, or which would affect the analysis if the<br>             disease/condition exacerbated during the study.<br><br>          -  Subjects who have ever received treatment with biological based therapy example,<br>             omalizumab, mepolizumab, for asthma.<br><br>          -  Subjects who have received an investigational drug and/or medical device within 30<br>             days of entry into this study (Screening), or within five drug half-lives of the<br>             investigational drug, whichever is longer.<br><br>          -  A subject will not be eligible for this study if he/she is an immediate family member<br>             of the participating investigator, sub-investigator, study coordinator, employee of<br>             the participating investigator, or any family member of a Propeller Health employee.<br>